nach oben

Modern Rheumatology

Erschienen in:

01.02.2009 | Case Report

A case report of a patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years

verfasst von: Hideko Nakahara, Toru Mima, Naoko Yoshio-Hoshino, Masato Matsushita, Jun Hashimoto, Norihiro Nishimoto

Erschienen in: Modern Rheumatology | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Interleukin-6 overproduction is pathologically involved in adult onset Still’s disease (AOSD). We successfully treated a man with refractory AOSD utilizing tocilizumab. Tocilizumab was discontinued after 15 doses due to intestinal bleeding, but the efficacy was sustained over 21 months. Tocilizumab was readministered safely upon recurrence and showed similar efficacy over 6 years. Corticosteroid and NSAIDs could be discontinued and intestinal bleeding was no more observed. Tocilizumab can be a therapeutic option for AOSD.

Bywaters EGL. Still’s disease in the adult. Ann Rheum Dis. 1971;30:121–33.PubMedCrossRef

Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;29:424–30.

Chen DY, Lan JL, Lin FJ, Hsieh TY. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still’s disease. J Rheumatol. 2004;31:2189–98.PubMed

Scheinberg MA, Chapira E, Fernandes ML, Hubscher O. Interleukin 6: a possible marker of disease activity in adult onset Still’s disease. Clin Exp Rheumatol 1992; 653–5.

Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatoid arthritis. Ann Rheum Dis. 2000;59(suppl 1):i21–7.PubMedCrossRef

Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, et al. Reshaping a human antibody to inhibit the interleukin-6-dependent tumor cell growth. Cancer Res. 1993;53:851–6.PubMed

Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:818–25.PubMedCrossRef

Woo P, Wilkinson N, Prieur AM, Southwood T, Leone V, Livermore P, et al. Open-label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7:R1281–8.PubMedCrossRef

Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006.PubMedCrossRef

10.

Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K. Humanized monoclonal anti-interleukin 6 receptor antibody for treatment of intractable adult-onset Still’s disease. Arthritis Rheum. 2002;46:3388–9.PubMedCrossRef

11.

Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162–7.PubMedCrossRef

12.

Information for proper use of infliximab (in Japanese) by Tanabe Seiyaku. http://medical.tanabe.co.jp/mstaff/remicade/index_remicade.shtml.

13.

Saiki O, Uda H, Nshimoto N, Miwa T, Mima T, Ogawara T, et al. Adult Still’s disease reflects a Th2 rather than a Th1 cytokine profile. Clin Immunol. 2004;112:120–5.PubMedCrossRef

14.

Olee T, Hashimoto S, Quach J, Lotz M. IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses. J Immunol. 1999;162:1096–100.PubMed

15.

Jablonska E, Jablonski J. Effect of IL-18 on the release of IL-6 and its soluble receptors: sIL-6Rα and sgp 130 by human neutrophils. Immunological Investigations. 2002;31:159–67.PubMedCrossRef

16.

Yamamura M, Kawashima M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, et al. Interferon-γ-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum. 2001;44:275–85.PubMedCrossRef

Titel: A case report of a patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years
verfasst von: Hideko Nakahara
Toru Mima
Naoko Yoshio-Hoshino
Masato Matsushita
Jun Hashimoto
Norihiro Nishimoto
Publikationsdatum: 01.02.2009
Verlag: Springer Japan
Erschienen in: Modern Rheumatology / Ausgabe 1/2009
Print ISSN: 1439-7595
Elektronische ISSN: 1439-7609
DOI: https://doi.org/10.1007/s10165-008-0116-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypertonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

A case report of a patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2009

Hyper-IgD syndrome with novel mutation in a Japanese girl

Clinical utility of computed tomographic scanning for the evaluation of lupus profundus in two patients with systemic lupus erythematosus

Sjogren’s syndrome: promising, new treatment options besides nizatidine

Response of early active rheumatoid arthritis to tumor necrosis factor inhibitors: evaluation by magnetic resonance imaging

Improvement in diagnosis and management of musculoskeletal conditions with one-stop clinic-based ultrasonography

Cyclosporin A treatment for Japanese patients with severe adult-onset Still’s disease

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin